Skip to content

Comparison of Postoperative Recovery Quality between Ciprofol and Propofol Total Intravenous Anesthesia in Patients Undergoing Laparoscopic Surgery: A Prospective, Randomized Controlled Trial

Comparison of Postoperative Recovery Quality between Ciprofol and Propofol Total Intravenous Anesthesia in Patients Undergoing Laparoscopic Surgery: A Prospective, Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500115831
Enrollment
Unknown
Registered
2025-12-31
Start date
2026-01-05
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients undergoing laparoscopic surgery?

Interventions

Propofol Group:Induction with propofol 2.0 mg/kg, maintenance with continuous infusion of propofol 4.0-10.0 mg/(kg·h), maintaining BIS between 40-60.
Ciprofol Group:Induction with ciprofol 0.4 mg/kg, maintenance with continuous infusion of ciprofol 0.8-1.5 mg/(kg·h), maintaining BIS between 40-60.

Sponsors

The First Affiliated Hospital of Soochow University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Signed informed consent; 2. Patients scheduled for elective laparoscopic surgery; 3. Patients with ASA physical status I-III; 4. Patients aged 18-70 years; 5. Patients with BMI between 18-28 kg/m^2.

Exclusion criteria

Exclusion criteria: 1. Patients with severe cardiopulmonary dysfunction; 2. Patients with severe hepatic or renal insufficiency; 3. Patients with anticipated difficult airway; 4. Patients with known allergy or contraindication to any drug used in this study; 5. Patients with neurological/psychiatric disorders or long-term use of hypnotics/sedatives; 6. Patients who are pregnant, lactating, or planning pregnancy; 7. Patients with cognitive impairment unable to cooperate with the 24-hour postoperative QoR-15 score assessment; 8) Other conditions deemed by the investigator as unsuitable for participation.

Design outcomes

Primary

MeasureTime frame
Quality of Recovery-15 (QoR-15) score on the first postoperative day;

Secondary

MeasureTime frame
QoR-15 score on the second postoperative day;Perioperative hemodynamic changes;Intraoperative use of vasoactive drugs;Dosage of study drugs;Time required for BIS <=60 after induction with the study drug;Extubation time;PACU length of stay;Incidence of other perioperative adverse events (e.g., intraoperative awareness, nausea and vomiting, postoperative fever, postoperative delirium, drowsiness, allergy) ;Patient satisfaction;

Countries

China

Contacts

Public ContactCheng Hao

The First Affiliated Hospital of Soochow University

chenghaojs@163.com+86 139 0261 7420

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026